OTHER INFORMATION.
−Removed: Independent Contractor and Director Fee Termination Agreement and Release, dated March 25, 2024, between the Company and Bruce Horowitz (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on March 26, 2024).
−Removed: Independent Contractor Agreement, dated March 25, 2024, between the Company and Dominic Rodrigues (incorporated by reference to Exhibit 10.2 of the Company’s current report on Form 8-K filed with the SEC on March 26, 2024).
−Removed: Exclusive License Agreement (with Equity), dated March 21, 2024, by and between the Company and University of Miami (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on March 27, 2024).
+Added: Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s current report on Form 8-K filed with the SEC on June 25, 2024).
+Added: Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 of the Company’s current report on Form 8-K filed with the SEC on June 25, 2024).
+Added: Form of Unsecured Convertible Promissory Note (incorporated by reference to Exhibit 4.1 of the Company’s current report on Form 8-K filed with the SEC on July 17, 2024).
Pershing Employment Agreement, dated April 16, 2024, between the Company and Ed Pershing (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on April 16, 2024).
Rodrigues Employment Agreement, dated April 16, 2024, between the Company and Dominic Rodrigues (incorporated by reference to Exhibit 10.2 of the Company’s current report on Form 8-K filed with the SEC on April 16, 2024).
+Added: Provectus Biopharmaceuticals, Inc.
+Added: 2024 Equity Compensation Program (incorporated by reference to Appendix C of the Company’s definitive proxy statement on Schedule 14A filed with the SEC on May 6, 2024).
+Added: Conversion Agreement, dated June 21, 2024, by and between the Company and Dominic Rodrigues (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on June 25, 2024).
+Added: 2024 Financing Term Sheet (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on July 17, 2024).
Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).
14 unchanged sentences
Definition Linkbase Document.
−Removed: Cover Page Interactive
−Removed: Data File (formatted as Inline XBRL and contained in Exhibit 101)
+Added: Cover Page Interactive Data
+Added: File (formatted as Inline XBRL and contained in Exhibit 101)
Filed herewith.
2 unchanged sentences
the undersigned thereunto duly authorized.
−Removed: PROVECTUS BIOPHARMACEUTICALS, INC.
−Removed: Dominic Rodrigues
+Added: BIOPHARMACEUTICALS, INC.
Dominic Rodrigues
−Removed: President (Principal Executive Officer)
−Removed: Heather Raines, CPA
−Removed: Chief Financial Officer (Principal Financial Officer)
+Added: (Principal Executive Officer)
+Added: Heather Raines
+Added: Financial Officer (Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.